Benefit, rather than safety, of cilostazol for long-term mortality in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized trials

International Journal of Cardiology

Volumn 153, Issue 1, 2011, Pages 74-76

  Takagi, Hisato ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Cilostazol; Meta analysis; Mortality; Percutaneous coronary intervention; Randomized controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; PLACEBO; THIENOPYRIDINE DERIVATIVE;

BARE METAL STENT; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY STENT; DRUG EFFECT; DRUG ELUTING STENT; DRUG SAFETY; HUMAN; LETTER; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 80054931549     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.07.072     Document Type: Article

References (28)

1. J.G. Regensteiner, J.E. Ware Jr., and W.J. McCarthy Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials J Am Geriatr Soc 50 2002 1939 1946
2. T.M. Chapman, and K.L. Goa Cilostazol: a review of its use in intermittent claudication Am J Cardiovasc Drugs 3 2003 117 138
3. M. Packer, J.R. Carver, and R.J. Rodeheffer Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group N Engl J Med 325 1991 1468 1475
4. W.R. Hiatt, S.R. Money, and E.P. Brass Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a study in long-term effects) J Vasc Surg 47 2008 330 336
5. C.M. Ahn, S.J. Hong, J.H. Park, J.S. Kim, and D.S. Lim Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up Heart Vessels Dec 9 2010 (Epub ahead of print)
6. Y.D. Chen, Y.L. Lu, Z.N. Jin, F. Yuan, and S.Z. Lü A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent Chin Med J (Engl) 119 2006 360 366
7. Y. Ahn, M.H. Jeong, and J.W. Jeong Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients-cilostazol for diabetic patients in drug-eluting stent (CIDES) trial Circ J 72 2008 35 39
8. J.W. Suh, S.P. Lee, and K.W. Park Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial J Am Coll Cardiol 57 2011 280 289
9. J.S. Douglas Jr., D.R. Holmes Jr., and D.J. Kereiakes Coronary stent restenosis in patients treated with cilostazol Circulation 112 2005 2826 2832
10. S.W. Lee, K.J. Chun, and S.W. Park Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG trials) Am J Cardiol 105 2010 168 173
11. S.W. Lee, S.W. Park, and Y.H. Kim A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions) trial J Am Coll Cardiol 57 2011 1264 1270
12. Y. Han, S. Wang, and Y. Li Cilostazol improves long-term outcomes after coronary stent implantation Am Heart J 150 2005 568
13. Y. Han, Y. Li, and S. Wang Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study Am Heart J 157 2009 733 739
14. H. Kamishirado, T. Inoue, and K. Mizoguchi Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis Am Heart J 144 2002 303 308
15. K. Kozuma, K. Hara, and M. Yamasaki Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation Am Heart J 141 2001 124 130
16. T. Kunishima, H. Musha, and F. Eto A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation Clin Ther 19 1997 1058 1066
17. S.J. Park Long-DES-II study investigators. Percutaneous treatment of LONG native coronary lesions with drug-eluting stent-II: cypher versus taxus, Long-DES-II Available on crtonline.org http://www.crtonline.org/flash.aspx?PAGE- ID=3397
18. P.K. Min, J.H. Jung, Y.G. Ko, D. Choi, Y. Jang, and W.H. Shim Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study Circ J 71 2007 1685 1690
19. M. Ochiai, K. Eto, and S. Takeshita Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction Am J Cardiol 84 1999 1074 1076 (A6, A9)
20. S.W. Park, C.W. Lee, and H.S. Kim Effects of cilostazol on angiographic restenosis after coronary stent placement Am J Cardiol 86 2000 499 503
21. J. Ge, Y. Han, and H. Jiang RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome J Cardiovasc Pharmacol 46 2005 162 166
22. M. Sekiguchi, H. Hoshizaki, H. Adachi, S. Ohshima, K. Taniguchi, and M. Kurabayashi Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol Circ J 68 2004 610 614
23. M. Sekiya, J. Funada, K. Watanabe, M. Miyagawa, and H. Akutsu Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis Am J Cardiol 82 1998 144 147
24. N. Takeyasu, S. Watanabe, Y. Noguchi, K. Ishikawa, Y. Fumikura, and I. Yamaguchi Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting Circ J 69 2005 780 785
25. E. Tsuchikane, O. Katoh, and S. Sumitsuji Impact of cilostazol on intimal proliferation after directional coronary atherectomy Am Heart J 135 1998 495 502
26. M. Yamasaki, K. Hara, and Y. Ikari Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation Cathet Cardiovasc Diagn 44 1998 387 391
27. D.L. Jennings, and J.S. Kalus Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis J Clin Pharmacol 50 2010 415 421
28. H. Takagi, and T. Umemoto A meta-analysis of randomized trials of triple versus dual antiplatelet therapy after stent-based percutaneous coronary intervention Int J Cardiol 150 2011 228 230